Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Degenerative disc disease is a spinal condition caused by the breakdown of intervertebral discs. The symptoms observed for degenerative disc disease are tingling or numbness in legs or difficulty in walking. This disease is diagnosed with physical examination, through X-rays or magnetic resonance imaging (MRI). The degenerative disc disease is most commonly seen in geriatric population and has caused lower back pain and neck pain in adults.  

The U.S. degenerative disc disease treatment market is estimated to have around 2.644 Mn patients suffering from degenerative disc disease (DDD) in 2021 and is expected to exhibit a CAGR of 5.9% during the forecast period (2021-2028).

Figure 1.U.S. Degenerative Disc Disease Treatment Market Share (%) in Terms of Value, By Treatment 2021

U.S. Degenerative Disc Disease Treatment  | Coherent Market Insights

Increasing cause of lower back pain & neck pain in adults and increasing geriatric population is expected to drive the market growth during the forecast period.

Increasing cause of lower back pain & neck pain in adults and increasing geriatric population in the U.S. is expected to drive the growth of the degenerative disc disease treatment market over the forecast period. For instance, according to the article published in the National Center of Biotechnology Information in May 2017, among adults 60% to 80% would experience back pain and 20% to 70% would experience neck pain that would interfere with their daily activities during their lifetime in the U.S.

request-sample

U.S. Degenerative Disc Disease Treatment Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 2.644 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 5.9% 2028 Value Projection: US$ 3.958  Mn
Geographies covered:
  • North America: U.S.
Segments covered:
  • By Treatment: Epidural Steroid Injections, Narcotics (Morphine, Methadone Hydrochloride, Codeine, Hydrocodone, Tramodol, Oxycodone, Others), Orthobiologics (Includes Biomolecular/Gene Therapy, Cell-based Therapy, and Tissue-engineered Products) (Phase I, Phase II, Phase III)
  • By Disease Indication: Early Stage, Mid Stage, Late Stage
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

AnGes Inc., Ankasa Regenerative Therapeutics, Inc., BIOPHARM GMBH, BioRestorative Therapies Inc., Biosplice Therapeutics, Inc., Bone Therapeutics SA, Cerapedics Inc, CO.DON, Creative Medical Technology Holdings, Inc., DiscGenics Inc., Eli Lilly and Company, Ferring Pharmaceuticals, FibroGenesis, Geistlich Pharma AG, Harbor View Medical Services, PC, Intralink-Spine, Inc., Isto Biologics, Johnson & Johnson, Kolon TissueGene Inc., Kunovus, Lineage Cell Therapeutics, Inc., Mesoblast, NC Biomatrix BV, Notogen Inc., Pfizer, Inc., R3 Stem Cell, Smith & Nephew, Spine BioPharma, Stayble Therapeutics AB, US Stem Cell Inc., and VIVEX Biologics, Inc.

Growth Drivers:
  • Increasing cause of lower back pain & neck pain in adults and increasing geriatric population
  • Robust product pipeline
Restraints & Challenges:
  • Potential side effects of drugs used in the treatment of degenerative disc disease
  • High cost of surgery

Figure 2 .U.S. Degenerative Disc Disease Treatment Market Share (%), By Disease Indication, 2021

U.S. Degenerative Disc Disease Treatment  | Coherent Market Insights

Increasing research and development for the treatment of degenerative disc disease is expected to drive the market growth during the forecast period.

Key players operating in the market are focusing on development of novel therapeutics for the treatment of degenerative disc disease which is expected to offer a lucrative opportunity for the market players to launch their novel products in the market. For instance, in March 2020, DiscGenics, Inc. announced that it had completed enrolment in its Phase I/II first in human U.S. clinical study of IDCT, an allogeneic, injectable Discogenic Cell therapy for degenerative disc disease (DDD)

U.S. Degenerative Disc Disease Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe with the World Health Organization declaring it as a public health emergency. According to the World Health Organization’s report, the manifestation of Coronavirus (COVID-19) has resulted in more than 33.6 million infected individuals in the U.S. as of July 16, 2021. COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. For instance, in the U.S., according to the U.S. Consumer Spending Report, there has been a huge plunge in consumer spending as people stayed home and avoided shopping, traveling or gathering in crowds and caused the economy to sink at an estimated annual rate of 32% in the April-June 2020 quarter. The direct impact of COVID-19 pandemic related to possible delays of surgical care in infected patients seems relatively small in the grand scheme. Overall, the indirect effects of the COVID-19 pandemic upon spinal care are noticeable. Such a deleterious impact can be traced to several factors such as the reallocation of hospital resources (such as nursing staff and ICU beds) to the care of patients with the Coronavirus as well as cancellation of elective surgeries and office visits in order to reduce the chances of disease spread. The combination of both of these has led to sudden and drastic changes in the daily routine of not only spine surgeons but also of other professionals involved in spine care, such as pain management and rehabilitation physicians, physical therapists, and occupational therapists. Such effects have been even more pronounced after several U.S. states and counties decreed ‘shelter-in-place’ policies. The COVID-19 pandemic has also greatly affected the daily operations of several healthcare industries. Cancel and delay in surgery   tend to percolate throughout the whole healthcare environment, with negative consequences upon ongoing clinical trials mainly related to cessation of patient enrollment as well as cancelled follow-up visits, imaging, and laboratory tests. All of these tend to extend the required time for the completion of clinical studies, data analysis and the U.S. Food and Drug Administration approval, with increased total costs for bringing such new technologies and drugs to the market for the treatment of degenerative disc disease.

 U.S. Degenerative Disc Disease Treatment Market: Restraint

The major factors that may hinder growth of the U.S. degenerative disc disease treatment market include potential side effects of drugs used in the treatment of degenerative disc disease and high cost of surgery. For instance, according to the article published in the Spine Health in 2015, the cervical artificial disc replacement surgery cost around US$ 35,000 in the U.S. Moreover, according to the New Choice Health, Inc., a medical adviser company, the average cost of disc replacement surgery procedures ranges from US$ 16,700 – US$ 45, 800 in the U.S.

Key Players

Major players operating in the U.S. degenerative disc disease treatment market include AnGes Inc., Ankasa Regenerative Therapeutics, Inc., BIOPHARM GMBH, BioRestorative Therapies Inc., Biosplice Therapeutics, Inc., Bone Therapeutics SA, Cerapedics Inc, CO.DON, Creative Medical Technology Holdings, Inc., DiscGenics Inc., Eli Lilly and Company, Ferring Pharmaceuticals, FibroGenesis, Geistlich Pharma AG, Harbor View Medical Services, PC, Intralink-Spine, Inc., Isto Biologics, Johnson & Johnson, Kolon TissueGene Inc., Kunovus, Lineage Cell Therapeutics, Inc., Mesoblast, NC Biomatrix BV, Notogen Inc., Pfizer, Inc., R3 Stem Cell, Smith & Nephew, Spine BioPharma, Stayble Therapeutics AB, US Stem Cell Inc., and VIVEX Biologics, Inc.

Degenerative disc disease refers to symptoms of back or neck pain caused by wear-and-tear on a spinal disc. In some cases, degenerative disc disease also cause weakness, numbness, and hot shooting pains in the arms or legs (radicular pain). Degenerative disc disease typically consists of a low-level chronic pain with intermittent episodes of more severe pain. Degenerative disc diseases are very frequent and debilitating disorders, and R&D activities surrounding this disease are highly cost intensive. Hence, many fund raising companies and manufacturers are engaged in raising funds for their research regarding the treatment of degenerative disc diseases. Depending upon the level of pain, degenerative disc disease can be treated with two common processes which are non-surgical and spinal fusion. Non-surgical treatments include medications, physical therapy, and chiropractic care. Whereas, spinal fusion is a procedure used to surgically treat degenerative disc disease.

Market Dynamics

Key players in the market are focused on growth strategies such as product launch and approval which is expected to drive the growth of market over forecast period. For instance, in April 2021, Cerapedics Inc. an ortho-biologics company, announced that the U.S. Food and Drug Administration (FDA) granted breakthrough device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD). Moreover, in February 2019, FibroGenesis, a company focused on regrowth of the spinal disc nucleus using its universal donor product CybroCell, announced that the U.S. FDA had cleared its investigational new drug (IND) protocol of CybroCell for human trials in the U.S., considered to be the first IND approval for a fibroblast cell therapy in a chronic condition of degenerative disc disease.

Key features of the study:

  • This report provides in-depth analysis of the U.S. degenerative disc disease treatment market, and provides market size (Mn patients) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S. degenerative disc disease treatment market  based on the following parameters – company highlights, financial overview, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include AnGes Inc., Ankasa Regenerative Therapeutics, Inc., BIOPHARM GMBH, BioRestorative Therapies Inc., Biosplice Therapeutics, Inc., Bone Therapeutics SA, Cerapedics Inc, CO.DON, Creative Medical Technology Holdings, Inc., DiscGenics Inc., Eli Lilly and Company, Ferring Pharmaceuticals, FibroGenesis, Geistlich Pharma AG, Harbor View Medical Services, PC, Intralink-Spine, Inc., Isto Biologics, Johnson & Johnson, Kolon TissueGene Inc., Kunovus, Lineage Cell Therapeutics, Inc., Mesoblast, NC Biomatrix BV, Notogen Inc., Pfizer, Inc., R3 Stem Cell, Smith & Nephew, Spine BioPharma, Stayble Therapeutics AB, US Stem Cell Inc., and VIVEX Biologics, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S. degenerative disc disease treatment market  report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. degenerative disc disease treatment market

Detailed Segmentation:

  • U.S. Degenerative Disc Disease Treatment Market, By Treatment:
    • By Treatment :
      • Epidural Steroid Injections
      • Narcotics
        • Morphine
        • Methadone Hydrochloride
        • Codeine
        • Hydrocodone
        • Tramodol
        • Oxycodone
        • Others
      • Orthobiologics (Includes Biomolecular/Gene Therapy, Cell-based Therapy, and Tissue-engineered Products)
        • Phase I
        • Phase II
        • Phase III
  • U.S. Degenerative Disc Disease Treatment Market, By Disease Indication :
      • Early Stage
      • Mid Stage
      • Late Stage
  • U.S. Degenerative Disc Disease Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • AnGes Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Overview
      • Strategy
    • Ankasa Regenerative Therapeutics, Inc.
    • BIOPHARM GMBH
    • BioRestorative Therapies Inc.
    • Biosplice Therapeutics, Inc.
    • Bone Therapeutics SA
    • Cerapedics Inc.
    • DON
    • Creative Medical Technology Holdings, Inc.
    • DiscGenics Inc.
    • Eli Lilly and Company
    • Ferring Pharmaceuticals
    • FibroGenesis
    • Geistlich Pharma AG
    • Harbor View Medical Services, PC
    • Intralink-Spine, Inc.
    • Isto Biologics
    • Johnson & Johnson
    • Kolon TissueGene Inc.
    • Kunovus
    • Lineage Cell Therapeutics, Inc.
    • Mesoblast
    • NC Biomatrix BV
    • Notogen Inc.
    • Pfizer, Inc.
    • R3 Stem Cell
    • Smith & Nephew
    • Spine BioPharma
    • Stayble Therapeutics AB
    • US Stem Cell Inc.
    • VIVEX Biologics, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Treatment
      • Market Snapshot, By Disease Indication
      • Market Snapshot, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Patient Journey
    • Epidemiology
    • Patient Funnel
    • Patient Treatment Journey and Patient Share, By Treatment Type
    • Patient Share By Product Type In Overall Diagnosed Population
    • DDD Patient Numbers, By Pfirrmann Grade
    • Product Launch/Approvals
    • Acquisition, Collaboration & Agreements
    • Key Developments
    • Therapeutic Landscape
    • Future Therapeutic Landscape
  4. U.S. Degenerative Disc Disease Treatment Market  – Impact of Coronavirus (COVID-19) Pandemic
    • Impact of Covid-19 on Supply and Demand of Degenerative Disc Disease Drugs
    • Impact on R&D activities of Degenerative Disc Disease therapeutics
  5.  U.S. Degenerative Disc Disease Treatment Market, By Treatment Type, 2017 – 2028, Million (Number of Patient)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018– 2028
      • Segment Trends
    • Epidural Steroid Injections
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
    •  Narcotics
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
        • Morphine
        • Methadone Hydrochloride
        • Codeine
        • Hydrocodone
        • Tramodol
        • Oxycodone
        • Others
    • Orthobiologics (Includes Biomolecular/Gene Therapy, Cell-based Therapy, and Tissue-engineered Products)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
        • Phase I
        • Phase II
        • Phase III
  6. U.S. Degenerative Disc Disease Treatment Market, By Disease Indication, 2017 – 2028, Million (Number of Patient)
    • Overview
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Early Stage
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
    • Mid Stage
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
    • Late Stage
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
  7. U.S. Degenerative Disc Disease Treatment Market, By Distribution Channel, 2017 – 2028, Million (Number of Patient)
    • Overview
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
    • Online Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • AnGes Inc.*
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Ankasa Regenerative Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • BIOPHARM GMBH
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • BioRestorative Therapies Inc.
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Biosplice Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Bone Therapeutics SA
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Cerapedics Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • DON
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Creative Medical Technology Holdings, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • DiscGenics Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Eli Lilly and Company
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Ferring Pharmaceuticals
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • FibroGenesis
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Geistlich Pharma AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Harbor View Medical Services, PC
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Intralink-Spine, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Isto Biologics
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Johnson & Johnson
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Kolon TissueGene Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Kunovus
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Lineage Cell Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Mesoblast
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • NC Biomatrix BV
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Notogen Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Pfizer, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • R3 Stem Cell
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Smith & Nephew
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Spine BioPharma
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • Stayble Therapeutics AB
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • US Stem Cell Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
      • VIVEX Biologics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategy
    • Analyst Views
  9. Section
    • Research Methodology
    • About us

*Browse 6 market data tables and 16 figures on "U.S. Degenerative Disc Disease Treatment Market ” - forecast to 2028

FAQgrowicon

Frequently Asked Questions

U.S. degenerative disc disease treatment market is estimated to have around 2.644 Mn patients suffering from DDD in 2021 and expected to exhibit a CAGR of 5.9% between 2021 and 2028.
Increasing cause of lower back pain & neck pain in adults and increasing geriatric population and robust product pipeline are expected to drive the market growth during the forecast period.
Narcotics segment is expected to hold a major market share in the market over the forecast period.
The major factors hampering growth of the market include increasing cause of lower back pain & neck pain in adults and increasing geriatric population and robust product pipeline.
Major players operating in the market include AnGes Inc., Ankasa Regenerative Therapeutics, Inc., BIOPHARM GMBH, BioRestorative Therapies Inc., Biosplice Therapeutics, Inc., Bone Therapeutics SA, Cerapedics Inc, CO.DON, Creative Medical Technology Holdings, Inc., DiscGenics Inc., Eli Lilly and Company, Ferring Pharmaceuticals, FibroGenesis, Geistlich Pharma AG, Harbor View Medical Services, PC, Intralink-Spine, Inc., Isto Biologics, Johnson & Johnson, Kolon TissueGene Inc., Kunovus, Lineage Cell Therapeutics, Inc., Mesoblast, NC Biomatrix BV, Notogen Inc., Pfizer, Inc., R3 Stem Cell, Smith & Nephew, Spine BioPharma, Stayble Therapeutics AB, US Stem Cell Inc., and VIVEX Biologics, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.